Table 2.

Key aspects of the clinical pharmacology of anti-amyloid monoclonal antibodies currently in development.

Anti-Amyloid Antibody	Formulation	Fixed Dose or Weight-Based Dosing	Administration Schedule	Titration Required	Stopped When Amyloid Plaque Levels are Not Detectable
Aducanumab	IV/SC	Weight-based	Q 4 weeks	Yes	No
Sabirnetug	IV	Weight-based	Q 4 weeks	Yes	No
Trontinemab	SC	Fixed	Q 2 weeks	Yes	No
Lecanemab	IV	Weight-based	Q 2 weeks	No	No
Donanemab	IV	Fixed	Q 4 weeks	Yes	Yes
Remternetug	IV/SC	Fixed	Q 4 weeks	Yes	Yes

IV – intravenous; Q – every; SC – subcutaneous.